Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Soon-Shiong's medical empire faces layoffs
Union-Tribune owner's anti-Covid 19 and cancer treatment progress slow
ImmunityBio assumed the $200 million state-subsidized plant's lease in August 2020, from Athenex, another biotech outfit.
More unsettling news regarding hiring at Union-Tribune owner Patrick Soon-Shiong's array of business ventures, this time on the medical side.
The Buffalo News is reporting that Soon-Shiong's ImmunityBio, Inc. will lay off 38 workers on December 1 at its Dunkirk manufacturing plant in upstate New York, citing a Worker Adjustment and Retraining Notification filing with the state.
ImmunityBio assumed the $200 million state-subsidized plant's lease in August 2020, from Athenex, another biotech outfit, concluding the deal in February of this year.
According to the paper's October 6 account, "ImmunityBio must hire 450 employees at the Dunkirk facility within the first five years of operations and also must spend $1.52 billion on operational expenses during the initial 10-year lease term, which started a year ago. It's not off to the best start."
"It's unclear how many workers are left at the Dunkirk facility," the story adds.
"State records obtained by the Buffalo News showed the plant had about 72 full-time jobs as of Dec. 31, 2021, when Athenex still had the lease. When the deal closed in February, more than 50 Athenex employees joined ImmunityBio, which planned to hire more workers."
The current "Reason for Dislocation," per a notice posted online by the New York State Department of Labor, is "Economic."
Back on January 26 of this year, Soon-Shiong told an upstate New York audience on Zoom that the plant would be used for the development of treatment for an array of maladies.
"We’ve made the decision that you and your body have the immune system that we can activate,” he was quoted by the Jamestown, New York Post-Journal as saying.
“We can change the paradigm of cancer, change the paradigm of infectious diseases and really use what’s called fusion proteins, cell therapy and vaccines to treat both cancer and COVID, HIV and TB.”
"Our goal is to enable a billion doses of RNA and adjuvants to be produced out of this plant."
"When asked about a start date, he replied, 'Quite literally, we needed this yesterday, so we are moving very fast, as fast as we can.'"
In August, Bloomberg News reported that part of a plant owned by Soon-Shiong in Cape Town, South Africa was being offered for rent "after a plunge in demand" for the Covid-19 vaccine he was developing.
"One of the two buildings in the A-grade facility with modern offices and a warehouse is available for lease as the owners of the campus wait for 'their production requirements to scale up,' according to Shane Howe, Broll Property Group’s regional head of industrial broking. The plans are still in the design phase, and nothing is being produced yet, he said."
Here's something you might be interested in.
Soon-Shiong's medical empire faces layoffs
Union-Tribune owner's anti-Covid 19 and cancer treatment progress slow
Soon-Shiong's medical empire faces layoffs
Union-Tribune owner's anti-Covid 19 and cancer treatment progress slow
ImmunityBio assumed the $200 million state-subsidized plant's lease in August 2020, from Athenex, another biotech outfit.
More unsettling news regarding hiring at Union-Tribune owner Patrick Soon-Shiong's array of business ventures, this time on the medical side.
The Buffalo News is reporting that Soon-Shiong's ImmunityBio, Inc. will lay off 38 workers on December 1 at its Dunkirk manufacturing plant in upstate New York, citing a Worker Adjustment and Retraining Notification filing with the state.
ImmunityBio assumed the $200 million state-subsidized plant's lease in August 2020, from Athenex, another biotech outfit, concluding the deal in February of this year.
According to the paper's October 6 account, "ImmunityBio must hire 450 employees at the Dunkirk facility within the first five years of operations and also must spend $1.52 billion on operational expenses during the initial 10-year lease term, which started a year ago. It's not off to the best start."
"It's unclear how many workers are left at the Dunkirk facility," the story adds.
"State records obtained by the Buffalo News showed the plant had about 72 full-time jobs as of Dec. 31, 2021, when Athenex still had the lease. When the deal closed in February, more than 50 Athenex employees joined ImmunityBio, which planned to hire more workers."
The current "Reason for Dislocation," per a notice posted online by the New York State Department of Labor, is "Economic."
Back on January 26 of this year, Soon-Shiong told an upstate New York audience on Zoom that the plant would be used for the development of treatment for an array of maladies.
"We’ve made the decision that you and your body have the immune system that we can activate,” he was quoted by the Jamestown, New York Post-Journal as saying.
“We can change the paradigm of cancer, change the paradigm of infectious diseases and really use what’s called fusion proteins, cell therapy and vaccines to treat both cancer and COVID, HIV and TB.”
"Our goal is to enable a billion doses of RNA and adjuvants to be produced out of this plant."
"When asked about a start date, he replied, 'Quite literally, we needed this yesterday, so we are moving very fast, as fast as we can.'"
In August, Bloomberg News reported that part of a plant owned by Soon-Shiong in Cape Town, South Africa was being offered for rent "after a plunge in demand" for the Covid-19 vaccine he was developing.
"One of the two buildings in the A-grade facility with modern offices and a warehouse is available for lease as the owners of the campus wait for 'their production requirements to scale up,' according to Shane Howe, Broll Property Group’s regional head of industrial broking. The plans are still in the design phase, and nothing is being produced yet, he said."
Comments